食品与发酵工业 >

2026 , Vol. 52 >Issue 11: 81 - 91

DOI: https://doi.org/10.13995/j.cnki.11-1802/ts.045376

研究报告

阿果糖浆对糖尿病小鼠糖脂代谢及肠道菌群结构的调节作用

  • 邢敏钰 ,
  • 王咪咪 ,
  • 张雅利 ,
  • 卢晓云 ,
  • 冉淦侨
展开
  • 1(陕西省生物农业研究所, 陕西 西安, 710043)
    2(西安交通大学 生命科学与技术学院, 陕西 西安, 710049)
第一作者:硕士,研究实习员(冉淦侨研究员为通信作者,E-mail:ranganqiao@163.com)

收稿日期: 2025-12-03

  修回日期: 2026-01-19

  网络出版日期: 2026-06-24

基金资助

陕西省科学院科技计划研究项目(2023k-21);陕西省生物农业研究所青年基金项目(2024SY03)

收起

Regulatory effects of psicose-fructose syrup on glucose-lipid metabolism and gut microbiota structure in diabetic mice

  • XING Minyu ,
  • WANG Mimi ,
  • ZHANG Yali ,
  • LU Xiaoyun ,
  • RAN Ganqiao
Expand
  • 1(Bio-Agriculture Institute of Shaanxi, Xi’an 710043, China)
    2(School of Life Science and Technology, Xi’an Jiaotong University, Xi’an 710049, China)

Received date: 2025-12-03

  Revised date: 2026-01-19

  Online published: 2026-06-24

Fold

摘要

探讨阿果糖浆对糖尿病小鼠糖脂代谢紊乱及肠道菌群失衡的调节作用,为其作为功能性食品配料的应用提供依据。采用高热能饮食与链脲佐菌素联合构建糖尿病小鼠模型,分别给予不同阿洛酮糖比例的阿果糖浆干预。检测进食量、体重、空腹血糖、胰岛素、口服葡萄糖耐量(oral glucose tolerance,OGTT)、糖化血红蛋白(glycated hemoglobin,HbA1c)、血脂谱、肝功能、甲状腺功能指标,并通过16S rRNA测序分析肠道菌群结构变化。阿果糖浆显著降低糖尿病小鼠的空腹血糖与HbA1c水平,改善葡萄糖耐量及胰岛素抵抗,其中HbA1c与胰岛素水平的改善幅度随阿洛酮糖含量增加而增强。血脂分析显示,阿果糖浆能显著降低甘油三酯(triglyceride,TG)水平,高阿洛酮糖比例组(DM-HPsi组)进一步显著提高高密度脂蛋白胆固醇(high-density lipoprotein cholesterol,HDL-C)含量;同时阿果糖浆能够显著降低谷丙转氨酶(alanine aminotransferase,ALT)和谷草转氨酶(aspartate aminotransferase,AST)活性,减轻糖尿病小鼠的肝功能损伤。肠道菌群分析显示,糖尿病模型小鼠存在显著菌群失调,表现为厚壁菌门/拟杆菌门比值下降、革兰氏阴性菌比例升高,以及拟杆菌属(Bacteroides)、另枝菌属(Alistipes)等有害菌丰度升高。阿果糖浆干预可显著逆转上述失衡,使厚壁菌门/拟杆菌门比值回升并显著提高布劳特氏菌属(Blautia)、粪杆菌属(Faecalibaculum)、罗姆布茨菌属(Romboutsia)、Mucispirillum、杜氏杆菌属(Dubosiella)等有益菌属丰度。阿果糖浆可改善糖尿病小鼠的糖脂代谢紊乱与肝功能损伤,表现出显著的降糖、调脂及护肝作用。同时,阿果糖浆可有效恢复糖尿病小鼠肠道菌群结构稳态,提升有益菌群丰度,显示出良好的微生态调节效应。该研究为阿果糖浆作为功能性食品在糖尿病及代谢综合征防治中的应用提供了实验依据。

关键词： 阿果糖浆; 糖尿病; 糖脂代谢; 肝功能; 肠道菌群

本文引用格式

邢敏钰 , 王咪咪 , 张雅利 , 卢晓云 , 冉淦侨 . 阿果糖浆对糖尿病小鼠糖脂代谢及肠道菌群结构的调节作用[J]. 食品与发酵工业, 2026 , 52(11) : 81 -91 . DOI: 10.13995/j.cnki.11-1802/ts.045376

Abstract

To investigate the regulatory effects of psicose-fructose syrup on glucose and lipid metabolism disorders and gut microbiota imbalance in diabetic mice, providing evidence for its application as a functional food ingredient.A diabetic mouse model was constructed using a high-energy diet combined with streptozotocin (STZ), and various proportions of D-psicose in psicose-fructose syrup were administered.The food intake, body weight, fasting blood glucose, insulin levels, oral glucose tolerance (OGTT), glycated hemoglobin (HbA1c), blood lipid profile, liver function, and thyroid function were measured.The gut microbiota structure was analyzed using 16S rRNA sequencing.Psicose-fructose syrup significantly reduced fasting blood glucose and HbA1c levels in diabetic mice, improving glucose tolerance and insulin resistance.The improvement in HbA1c and insulin levels was more pronounced with higher D-psicose content.Blood lipid analysis showed that psicose-fructose syrup significantly reduced triglyceride (TG) levels, and the high D-psicose group (DM-HPsi group) further significantly increased high-density lipoprotein cholesterol (HDL-C).Additionally, psicose-fructose syrup significantly lowered the activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), alleviating liver damage in diabetic mice.Gut microbiota analysis showed significant dysbiosis in the diabetic mice model, characterized by a decreased Firmicutes/Bacteroidetes ratio, an increased proportion of Gram-negative bacteria, and a higher abundance of harmful bacteria such as Bacteroides and Alistipes.Intervention with psicose-fructose syrup significantly reversed this imbalance, restoring the Firmicutes/Bacteroidetes ratio and significantly increasing the abundance of beneficial bacteria, including Blautia, Faecalibaculum, Romboutsia, Mucispirillum and Dubosiella.Psicose-fructose syrup improves glucose and lipid metabolism disorders and liver damage in diabetic mice, exhibiting significant hypoglycemic, lipid-regulating, and hepatoprotective effects.It also effectively restores the gut microbiota structure, enhancing the abundance of beneficial bacteria, demonstrating a favorable microecological regulation effect.This study provides experimental evidence for the application of psicose-fructose syrup as a functional food in the prevention and treatment of diabetes and metabolic syndrome.

Key words： psicose-fructose syrup; diabetic; glucose and lipid metabolism; liver function; gut microbiota

参考文献

[1] TAYLOR R.Insulin resistance and type 2 diabetes[J].Diabetes, 2012, 61(4):778-779.
[2] DEDANIA S R, PATEL V K, SONI S S, et al.Immobilization of Agrobacterium tumefaciens D-psicose 3-epimerase onto titanium dioxide for bioconversion of rare sugar[J].Enzyme and Microbial Technology, 2020, 140:109605.
[3] HAYASHI N, IIDA T, YAMADA T, et al.Study on the postprandial blood glucose suppression effect of D-psicose in borderline diabetes and the safety of long-term ingestion by normal human subjects[J].Bioscience, Biotechnology, and Biochemistry, 2010, 74(3):510-519.
[4] HOSSAIN M A, KITAGAKI S, NAKANO D, et al.Rare sugar D-psicose improves insulin sensitivity and glucose tolerance in type 2 diabetes Otsuka Long-Evans Tokushima Fatty (OLETF) rats[J].Biochemical and Biophysical Research Communications, 2011, 405(1):7-12.
[5] RAN G Q, TAN D, ZHAO J P, et al.Functionalized polyhydroxyalkanoate nano-beads as a stable biocatalyst for cost-effective production of the rare sugar D-allulose[J].Bioresource Technology, 2019, 289:121673.
[6] 邢敏钰, 龚俊波, 杜世超, 等.基于JMP软件分析的D-阿洛酮糖结晶工艺研究[J].中国食品添加剂, 2023, 34(8):1-9.
XING M Y, GONG J B, DU S C, et al.Optimization of crystallization process of D-psicose based on JMP software analysis[J].China Food Additives, 2023, 34(8):1-9.
[7] ATHYROS V G, DOUMAS M, IMPRIALOS K P, et al.Diabetes and lipid metabolism[J].Hormones, 2018, 17(1):61-67.
[8] WANG L Q, YAN N, ZHANG M, et al.The association between blood glucose levels and lipids or lipid ratios in type 2 diabetes patients:A cross-sectional study[J].Frontiers in Endocrinology, 2022, 13:969080.
[9] DE SILVA N M G, BORGES M C, HINGORANI A D, et al.Liver function and risk of type 2 diabetes:Bidirectional Mendelian randomization study[J].Diabetes, 2019, 68(8):1681-1691.
[10] LI J Q, YUAN W J, LIU J, et al.Association between Helicobacter pylori infection and type 2 diabetes mellitus:A retrospective cohort study and bioinformatics analysis[J].BMC Endocrine Disorders, 2024, 24(1):168.
[11] LIAQAT I, ALI N M, ARSHAD N, et al.Gut dysbiosis, inflammation and type 2 diabetes in mice using synthetic gut microbiota from diabetic humans[J].Brazilian Journal of Biology, 2021, 83:e242818.
[12] ZHANG H Y, MA L, PENG W B, et al.Association between gut microbiota and onset of type 2 diabetes mellitus:A two-sample Mendelian randomization study[J].Frontiers in Cellular and Infection Microbiology, 2024, 14:1327032.
[13] GUO Q, GAO Z Z, ZHAO L H, et al.Multiomics analyses with stool-type stratification in patient cohorts and Blautia identification as a potential bacterial modulator in type 2 diabetes mellitus[J].Diabetes, 2024, 73(3):511-527.
[14] MA Q Y, ZHAI R H, XIE X Q, et al.Hypoglycemic effects of Lycium barbarum polysaccharide in type 2 diabetes mellitus mice via modulating gut microbiota[J].Frontiers in Nutrition, 2022, 9:916271.
[15] MIZUMA S, HAYAKAWA M, HIRA T.Intestinal distension induced by luminal D-allulose promotes GLP-1 secretion in male rats[J].Endocrinology, 2025, 166(2):bqaf002.
[16] FRANCHI F, YARANOV D M, ROLLINI F, et al.Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load:Results of a prospective, randomized, crossover study[J].BMJ Open Diabetes Research & Care, 2021, 9(1):e001939.
[17] JAPAR S, FUKUNAGA K, KOBAYASHI T, et al.A pilot study on the effect of D-allulose on postprandial glucose levels in patients with type 2 diabetes mellitus during Ramadan fasting[J].Diabetology & Metabolic Syndrome, 2022, 14(1):86.
[18] TEYSSEIRE F, BORDIER V, BUDZINSKA A, et al.Metabolic effects and safety aspects of acute D-allulose and erythritol administration in healthy subjects[J].Nutrients, 2023, 15(2):458.
[19] FUKUNAGA K, YOSHIMURA T, IMACHI H, et al.A pilot study on the efficacy of a diabetic diet containing the rare sugar D-allulose in patients with type 2 diabetes mellitus:A prospective, randomized, single-blind, crossover study[J].Nutrients, 2023, 15(12):2802.
[20] KÖROĞLU E, CANBAKAN B, ATAY K, et al.Role of oxidative stress and insulin resistance in disease severity of non-alcoholic fatty liver disease[J].The Turkish Journal of Gastroenterology, 2016, 27(4):361-366.
[21] GOU Y, LIU B Y, CHENG M Y, et al.D-allulose ameliorates skeletal muscle insulin resistance in high-fat diet-fed rats[J].Molecules, 2021, 26(20):6310.
[22] KHAN R S, BRIL F, CUSI K, et al.Modulation of insulin resistance in nonalcoholic fatty liver disease[J].Hepatology, 2019, 70(2):711-724.
[23] KUSNADI Y, SALEH M I, ALI Z, et al.Firmicutes/bacteroidetes ratio of gut microbiota and its relationships with clinical parameters of type 2 diabetes mellitus:A systematic review[J].Open Access Macedonian Journal of Medical Sciences, 2023, 11:67-72.
[24] AHMED K, CHOI H N, CHO S R, et al.Association of firmicutes/bacteroidetes ratio with body mass index in Korean type 2 diabetes mellitus patients[J].Metabolites, 2024, 14(10):518.
[25] HUNG W C, HUNG W W, TSAI H J, et al.The association of targeted gut microbiota with body composition in type 2 diabetes mellitus[J].International Journal of Medical Sciences, 2021, 18(2):511-519.
[26] HUANG Z R, HUANG Q Z, CHEN K W, et al.Sanghuangporus vaninii fruit body polysaccharide alleviates hyperglycemia and hyperlipidemia via modulating intestinal microflora in type 2 diabetic mice[J].Frontiers in Nutrition, 2022, 9:1013466.
[27] 陈茜, 薛勇, 宋晓峰, 等.糖尿病及糖尿病心血管并发症患者肠道菌群的特征[J].微生物学报, 2019, 59(9):1660-1673.
CHEN X, XUE Y, SONG X F, et al.Gut microbiota in diabetic patients and diabetic patients with cardiovascular complications[J].Acta Microbiologica Sinica, 2019, 59(9):1660-1673.
[28] SALGUERO M V, AL-OBAIDE M A I, SINGH R, et al.Dysbiosis of Gram-negative gut microbiota and the associated serum lipopolysaccharide exacerbates inflammation in type 2 diabetic patients with chronic kidney disease[J].Experimental and Therapeutic Medicine, 2019, 18(5):3461-3469.
[29] LIU N N, YAN X H, LYU B H, et al.A study on the association between gut microbiota, inflammation, and type 2 diabetes[J].Applied Microbiology and Biotechnology, 2024, 108(1):213.
[30] MAZHAR M, ZHU Y, QIN L K.The interplay of dietary fibers and intestinal microbiota affects type 2 diabetes by generating short-chain fatty acids[J].Foods, 2023, 12(5):1023.
[31] TANG R Q, LI L J.Modulation of short-chain fatty acids as potential therapy method for type 2 diabetes mellitus[J].Canadian Journal of Infectious Diseases and Medical Microbiology, 2021, 2021(1):6632266.
[32] HERP S, BRUGIROUX S, GARZETTI D, et al.Mucispirillum schaedleri antagonizes Salmonella virulence to protect mice against colitis[J].Cell Host & Microbe, 2019, 25(5):681-694.
[33] BAI Y F, WANG S W, WANG X X, et al.The flavonoid-rich Quzhou Fructus Aurantii extract modulates gut microbiota and prevents obesity in high-fat diet-fed mice[J].Nutrition & Diabetes, 2019, 9:30.
[34] AI X J, WU C L, YIN T T, et al.Antidiabetic function of Lactobacillus fermentum MF423-fermented rice bran and its effect on gut microbiota structure in type 2 diabetic mice[J].Frontiers in Microbiology, 2021, 12:682290.
[35] LI Y C, WANG W X, LIU Y X, et al.Diminished immune response and elevated abundance in gut microbe Dubosiella in mouse models of chronic colitis with GBP5 deficiency[J].Biomolecules, 2024, 14(7):873.
Options
文章导航

/

〈 〉

技术支持：北京玛格泰克科技发展有限公司